Patents by Inventor Rémi Meyrueix
Rémi Meyrueix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10052289Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.Type: GrantFiled: December 18, 2009Date of Patent: August 21, 2018Assignee: Flamel Ireland LimitedInventors: Rémi Meyrueix, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
-
Patent number: 10004693Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: GrantFiled: January 26, 2011Date of Patent: June 26, 2018Assignee: Flamel Ireland LimitedInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 9814684Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: GrantFiled: September 9, 2015Date of Patent: November 14, 2017Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20170281558Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20150374636Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: September 9, 2015Publication date: December 31, 2015Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20150374635Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: September 9, 2015Publication date: December 31, 2015Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 8734850Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.Type: GrantFiled: November 24, 2004Date of Patent: May 27, 2014Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula
-
Patent number: 8652523Abstract: The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles, should have a coating film of sufficient thickness to ensure controlled permeability and should be adapted to industrial reproduction. This is achieved by the inventive microcapsules of mean diameter less than 1000 microns, and whereof the coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA).Type: GrantFiled: July 28, 2003Date of Patent: February 18, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyrueix
-
Publication number: 20120294832Abstract: The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000 g/mol, preferably approximately 33,000 g/mol and carrying grafts of alpha-tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. It also relates to the use of such a solid composition for the preparation of a liquid composition by the addition of an aqueous liquid.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: Flamel TechnologiesInventors: Gauthier Pouliquen, You-Ping Chan, Rémi Meyrueix, David Chognot, Roger Kravtzoff
-
Patent number: 8236353Abstract: The present invention relates to pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time. The invention relates to a liquid formulation comprising at least one active principle (AP) and an aqueous suspension based on colloidal particles of a polymer (PO), wherein said formulation satisfies the following four conditions: (a) the PO is a polyamino acid comprising glutamic residues, wherein some glutamic residues each carry a pendant cationic group (CG), said CG being identical or different from one another, and other glutamic residues each carry a pendent hydrophobic group (GH), said GH being identical or different from one another, (b) the pHf value of the pH of said formulation is between 3.0 and 6.5; (c) at the pHf value, the PO forms a colloidal solution which associates spontaneously and noncovalently with the AP; (d) 1 ml of said formulation precipitates during mixing with a volume of 1 ml of a test buffer solution Tp.Type: GrantFiled: May 5, 2008Date of Patent: August 7, 2012Assignee: Flamel TechnologiesInventors: Frédéric Checot, Cecile Bonnet-Gonnet, You-Ping Chan, Olivier Breyne, Remi Meyrueix
-
Publication number: 20120156256Abstract: The present invention relates to novel nanoparticles formed by at least one active ingredient and by at least two polyelectrolytes of opposite polarity, in particular characterized in that at least one of the two polyelectrolytes bears hydrophobic side groups and at least one of the two polyelectrolytes bears side groups of the polyalkylene glycol type, said nanoparticles having an average diameter ranging from 10 to 100 nm and comprising a quantity of groups of the polyalkylene glycol type such that the mass ratio wPAG of polyalkylene glycol relative to the total polymer is greater than or equal to 0.05.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: Flamel TechnologiesInventors: Cecile Bonnet-Gonnet, Rémi Meyrueix
-
Patent number: 8197850Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.Type: GrantFiled: November 19, 2001Date of Patent: June 12, 2012Assignee: Flamel TechnologiesInventors: Catherine Castan, Remi Meyrueix, Gerard Soula
-
Patent number: 8101209Abstract: The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 ?m) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5.Type: GrantFiled: April 19, 2004Date of Patent: January 24, 2012Assignee: Flamel TechnologiesInventors: Valérie Legrand, Catherine Castan, Rémi Meyrueix, Gérard Soula
-
Patent number: 8084045Abstract: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active principle(s) that makes it possible, after parenteral injection, to increase significantly the in vivo release time of a therapeutic protein while at the same time reducing the plasma concentration peak of the active protein, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance.Type: GrantFiled: November 19, 2004Date of Patent: December 27, 2011Assignee: Flamel TechnologiesInventors: Gauthier Pouliquen, Olivier Soula, Rémi Meyrueix, Florence Nicolas
-
Patent number: 8017156Abstract: The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. The essential object of the invention is to provide an injectable long-acting insulin formulation in the form of a colloidal suspension which is stable, which has a good local tolerance and toxicity compatible with the chronic treatment of diabetics, and which maintains a substantial hypoglycemic effect extending over at least 24 hours after a single administration, e.g. by the subcutaneous route. To achieve this object, the invention relates to a stable aqueous colloidal formulation of insulin-laden nanoparticles of at least one poly(Leu-block-Glu) in which the pH is between 5.8 and 7.0, the osmolarity O (in mOsmol) . . . : 270?O?800, and the viscosity v (in mPa·s) is low, namely v?40. The nanoparticles of poly(Leu-block-Glu) have a mean hydrodynamic diameter Dh such that: 15?Dh?40.Type: GrantFiled: June 9, 2005Date of Patent: September 13, 2011Assignee: Flamel TechnologiesInventors: Alain Constancis, Florence Nicolas, Rémi Meyrueix, Olivier Soula
-
Publication number: 20110129539Abstract: The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of amoxicillin and consisting of suspensions of coated particles of amoxicillin (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of amoxicillin, in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of amoxicillin, said liquid phase being furthermore saturated with amoxicillin.Type: ApplicationFiled: February 10, 2011Publication date: June 2, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20110117205Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: January 26, 2011Publication date: May 19, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 7910133Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of amoxicillin, said formulations consisting of suspensions of coated particles of amoxicillin (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the amoxicillin according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the amoxicillin, this liquid phase furthermore being saturated with amoxicillin.Type: GrantFiled: April 7, 2003Date of Patent: March 22, 2011Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 7906145Abstract: The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of active principle(s) excluding amoxicillin and consisting of suspensions of coated particles of active principles (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of the active principle(s), in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of the active principle, said liquid phase being furthermore saturated with active principle(s).Type: GrantFiled: April 7, 2003Date of Patent: March 15, 2011Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: RE47084Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.Type: GrantFiled: May 27, 2016Date of Patent: October 16, 2018Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula